Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 8/20 | 0.45 |
| ▸ | DRD5 | P21918 | 8/20 | 0.45 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | DRD3 | P35462 | 6/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 5/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719733 | 0.81 | HTR2C (0.42) | DRD2 | |
| SCHEMBL719710 | 0.78 | CYP1A2 (0.46) | DRD1DRD5DRD2DRD3MAOA | |
| SCHEMBL719716 | 0.77 | MAOA (0.44) | DRD1DRD5DRD2DRD3MAOA | |
| SCHEMBL719099 | 0.77 | DRD2 (0.44) | DRD1DRD5DRD2DRD3MAOA | |
| SCHEMBL4216096 | 0.75 | KDM4E (0.55) | — | |
| SCHEMBL4214343 | 0.74 | HTR3A (0.54) | — | |
| Trifluoroacetic Acid SCHEMBL720167 | 0.70 | KDM1A (0.39) | PRMT5WDR77 | |
| SCHEMBL719896 | 0.70 | CHKA (0.48) | DRD2MAOAMAOBSLC6A4 | |
| SCHEMBL31046620 | 0.69 | CYP2C19 (0.47) | DRD1DRD5DRD2DRD3MAOA | |
| SCHEMBL18034936 | 0.69 | CYP2C19 (0.47) | DRD1DRD5DRD2DRD3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | claimed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | claimed |
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010096384-A2 | FUSED BENZAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | TARGACEPT, INC. (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053168-A1 | FUSED BENZOAZEPINES AS NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA2, CHRNA5, CHRNA10 | DRD1 537/4885DRD5 702/4885DRD2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.